Concurrent acalabrutinib, bendamustine, and rituximab in the first-line setting improved outcomes for patients with mantle cell lymphoma (MCL) relative to sequential treatment without acalabrutinib.
The rate of severe infections decreased from 2 infections to 0.2 infections per PYO after treatment with etuvetidigene autotemcel.
LumosityRx is a prescription therapeutic app that includes 13 cognitive training games targeting key brain processes connected to attention function.
Findings seen for older adults experiencing gabapentinoid (gabapentin and pregabalin)-edema-loop diuretic prescribing cascade ...
The homeopathic nasal spray is used to temporarily relieve nasal symptoms associated with cold and flu, including congestion and rhinorrhea. The recalled product, which has a lot number of 224268 and ...
HealthDay News — A widely used blood pressure medication is being pulled from shelves after testing suggested some batches may contain traces of other drugs. Glenmark Pharmaceuticals has recalled ...
Researchers assessed whether a set dose of luspatercept could be safe in treating pediatric patients with non–transfusion dependent beta-thalassemia.
Researchers sought to determine whether zanubrutinib plus obinutuzumab would be effective in treating patients with R/R FL.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results